ERIN GOLEC: Open Payments
NPI 1891960712 · SALINAS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,066 in 43 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $156 · 2025 $1,066
Food & beverage: $871Education: $195
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $301 |
| GlaxoSmithKline, LLC. | 17 | $264 |
| Regeneron Healthcare Solutions, Inc. | 2 | $123 |
| Verona Pharma, Inc. | 5 | $106 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| GENZYME CORPORATION | 4 | $97 |
| Genentech USA, Inc. | 1 | $23 |
| Insmed, Inc. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
| Amgen Inc. | 1 | $15 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, Ohtuvayre, TRELEGY ELLIPTA, BREZTRI, FASENRA, Xolair.
Industry payments across CA — which companies pay providers there.
